Mesoblast
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2001-01-01
- Employees
- 73
- Market Cap
- $733.9M
- Website
- http://www.angioblast.com
- Introduction
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 200...
Safety Follow-up of Treatment With Remestemcel-L in Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute GVHD
- Conditions
- Interventions
- First Posted Date
- 2016-01-11
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- Mesoblast, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT02652130
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸CHOC Children's Hospital of Orange County, Orange, California, United States
🇺🇸UCSF Benioff Children's Hospital, San Francisco, California, United States
A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD)
- First Posted Date
- 2015-01-12
- Last Posted Date
- 2022-03-17
- Lead Sponsor
- Mesoblast, Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT02336230
- Locations
- 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
🇺🇸University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸Fred Hutchinson Cancer Research, Seattle, Washington, United States
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
- Conditions
- Interventions
- First Posted Date
- 2014-01-09
- Last Posted Date
- 2022-01-10
- Lead Sponsor
- Mesoblast, Inc.
- Target Recruit Count
- 566
- Registration Number
- NCT02032004
- Locations
- 🇺🇸
Mesoblast Investigational Site 10775 - Cedars-Sinai Medical Care Foundation, Los Angeles, California, United States
🇺🇸Mesoblast Investigational Site 13027 - Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸Mesoblast Investigational Site 10772 - University Cardiologist, Rush University Medical Center, Chicago, Illinois, United States
Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction
- Conditions
- Interventions
- First Posted Date
- 2013-02-01
- Last Posted Date
- 2022-06-23
- Lead Sponsor
- Mesoblast, Inc.
- Target Recruit Count
- 106
- Registration Number
- NCT01781390
Safety and Treatment Outcome Study of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects With Treatment-resistant Crohn's Disease
- Conditions
- First Posted Date
- 2012-01-16
- Last Posted Date
- 2020-03-10
- Lead Sponsor
- Mesoblast, Inc.
- Registration Number
- NCT01510431
- Locations
- 🇺🇸
Unviersity of California, San Francisco, San Francisco, California, United States
🇺🇸Mount Sinai Hospital, New York, New York, United States
🇺🇸Stormont-Vail, Topeka, Kansas, United States
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
- First Posted Date
- 2010-11-03
- Last Posted Date
- 2021-12-08
- Lead Sponsor
- Mesoblast, Inc.
- Target Recruit Count
- 73
- Registration Number
- NCT01233960
- Locations
- 🇦🇺
Royal Melbourne Hospital, Melbourne, Victoria, Australia
🇺🇸Shafran Gastroenterology Center, Winter Park, Florida, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI)
- First Posted Date
- 2009-04-08
- Last Posted Date
- 2022-01-13
- Lead Sponsor
- Mesoblast, Inc.
- Target Recruit Count
- 220
- Registration Number
- NCT00877903
- Locations
- 🇺🇸
Mercy Gilbert Medical Center / Catholic Health Care West, Gilbert, Arizona, United States
🇺🇸Drexel University College of Medicine, Philadelphia, Pennsylvania, United States
🇺🇸University of Miami, Miami, Florida, United States
Prochymal® Expanded Access for Adults Who Have Failed Steroid Treatment for Acute Graft Versus Host Disease (GVHD)
- Conditions
- First Posted Date
- 2009-01-21
- Last Posted Date
- 2020-03-09
- Lead Sponsor
- Mesoblast, Inc.
- Registration Number
- NCT00826046
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Indiana BMT, Beech Grove, Indiana, United States
Prochymal Expanded Access Treatment for Pediatric Patients Who Have Failed Steroids for Acute GVHD
- First Posted Date
- 2008-09-25
- Last Posted Date
- 2020-03-09
- Lead Sponsor
- Mesoblast, Inc.
- Registration Number
- NCT00759018
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Medical University of South Carolina, Charleston, South Carolina, United States
🇨🇦CHU Sainte-Justine, Montreal, Quebec, Canada
PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)
- Conditions
- Interventions
- First Posted Date
- 2008-06-04
- Last Posted Date
- 2021-12-23
- Lead Sponsor
- Mesoblast, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT00690066
- Locations
- 🇺🇸
Desert Endocrinology CRC, Henderson, Nevada, United States
🇺🇸Cumberland Valley Endocrinology, Carlisle, Pennsylvania, United States
🇺🇸AM Diabetes & Endocrinology Center, Bartlett, Tennessee, United States